| Literature DB >> 35889967 |
Isabeau Wiencek1, Maria Hartmann2, Jörg Merkel3, Sara Trittmacher1, Lothar Kreienbrock2, Isabel Hennig-Pauka1.
Abstract
Glaesserella parasuis (Gps) causes high economic losses in pig farms worldwide. So far no vaccine provides cross-protection for different serotypes, so antibiotic treatment is widely used to cope with this pathogen. In this study, routine diagnostic data from 2046 pigs with Gps related diseases sent for necropsy to a German laboratory in the time period 2006-2021 were analysed retrospectively. In the time period 2018-2021, the most frequent serotypes (ST) detected were ST4 (30%) and ST13 (22%). A comparison of the reference period 2006-2013 prior to obligatory routine recording of antimicrobial usage in livestock with the period 2014-2021 resulted in a statistically significant decrease of frequencies of resistant Gps isolates for ceftiofur, enrofloxacin, erythromycin, spectinomycin, tiamulin and tilmicosin. While in 2006-2013 all isolates were resistant for tetracyclin and cephalothin, frequencies of resistant isolates decreased in the second time period to 28% and 62%, respectively. Parallel to the reduction of antimicrobial usage, during recent years a reduction in resistant Gps isolates has been observed, so only a low risk of treatment failure exists. Most frequently, pigs positive for Gps were also positive for S.suis (25.4%), PRRSV-EU (25.1%) and influenza virus (23%). The viral pathogens may act as potential trigger factors.Entities:
Keywords: Glaesser’s disease; Gps serotypes; Streptococcus suis; antibiotic resistance; endemic infection; influenza virus; porcine reproductive and respiratory syndrome virus; respiratory disease; susceptibility
Year: 2022 PMID: 35889967 PMCID: PMC9316560 DOI: 10.3390/pathogens11070721
Source DB: PubMed Journal: Pathogens ISSN: 2076-0817
Serotypes of Gps in a subset of isolates (n = 101) from the years 2018–2021.
| Gps Serotype | Number of Isolates | Proportion of Isolates (%) |
|---|---|---|
| 1 | 8 | 7.9 |
| 2 | 1 | 1.0 |
| 1/2 | 2 | 2.0 |
| 4 | 30 | 29.7 |
| 5/12 | 13 | 12.9 |
| 7 | 13 | 12.9 |
| 9 | 7 | 6.9 |
| 10 | 1 | 1.0 |
| 11 | 1 | 1.0 |
| 13 | 22 | 21.8 |
| 14 | 1 | 1.2 |
| 15 | 2 | 2.0 |
Distribution of Gps isolates originating from different sampling sites and age groups (n = 2046 pigs).
| Sampling Site | Suckling Piglets | Nursery Pigs | Fatteners | Sows | No Age Group | All Samples | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| % |
| % |
| % |
| % |
| % |
| % | |
| Respiratory tract | 118 | 73.3 | 1252 | 83.7 | 60 | 76.9 | 2 | 40.0 | 265 | 86.6 | 1697 | 82.9 |
| Pericardium | 18 | 11.2 | 104 | 7.0 | 5 | 6.4 | 2 | 40.0 | 10 | 3.3 | 139 | 6.8 |
| Pleural cavity | 8 | 5.0 | 59 | 3.9 | 4 | 5.1 | − | − | 13 | 4.2 | 84 | 4.1 |
| Brain | 7 | 4.3 | 44 | 2.9 | 7 | 9.0 | − | − | 12 | 3.9 | 70 | 3.4 |
| Joint | 6 | 3.7 | 18 | 1.2 | 2 | 2.6 | 1 | 20.0 | 1 | 0.3 | 28 | 1.4 |
| Abdominal cavity | 3 | 1.9 | 19 | 1.3 | − | − | − | − | 1 | 0.3 | 23 | 1.1 |
| Nose | 1 | 0.6 | − | − | − | − | − | − | 4 | 1.3 | ||
| Total | 161 | 100 | 1496 | 100 | 78 | 100 | 5 | 100 | 306 | 100 | 2046 | 100 |
− No isolates avaliable.
Distribution of a subgroup of n = 54 Gps strains tested for the vta gene.
| Gps Isolates Positive for LS vta | Serotypes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 4 | 5/12 | 7 | 9 | 11 | 13 | 14 | 15 | n.s. * | Total | |
| Respiratory tract | 1 | 16 | 7 | 6 | 1 | 1 | 6 | 1 | 1 | 5 | 45 |
| Other sites | − | − | 2 | 2 | 1 | − | 2 | − | − | 2 | 9 |
| Total | 1 | 16 | 9 | 8 | 2 | 1 | 8 | 1 | 1 | 7 | 54 |
All strains were found to be positive for the vta gene. * not serotyped. − not tested.
Results of antimicrobial susceptibility testing of Gps isolates (n = 2046).
| Substance (Clinical Breakpoint (mg/L)) | Number of Isolates with MIC Values (mg/L) of | MIC50 | MIC90 | s | i | r | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ≤0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | ≥64 | (mg/L) | % | % | % | ||
| Ampicillin (≤0.5) | 2046 | − | − | 1372 | 260 | 128 | 57 | 48 | 29 | 28 | 39 | 33 | 52 | ≤0.13 | 2.00 | 86.02 | 2.79 | 11.19 |
| Ceftiofur (≤2) | 2046 | − | − | 313 | 5 | 3 | 1670 | 13 | 6 | − | 36 | − | − | 1.00 | 1.00 | 97.95 | 0.29 | 1.80 |
| Cephalothin 1 (≤8) | 2046 | − | − | − | − | − | 291 | 16 | 1637 | 46 | 42 | 6 | 8 | 4.00 | 4.00 | 15.00 | 80.00 | 5.00 |
| Colistin (<0.5) | 2046 | − | − | − | − | 1868 | 91 | 16 | 4 | 67 | − | − | − | 0.50 | 0.50 | 91.30 | 5.20 | 3.50 |
| Enrofloxacin (≤0.25) | 2046 | 281 | 1503 | 108 | 68 | 63 | 12 | 8 | 3 | − | − | − | − | 0.06 | 0.13 | 95.80 | 3.10 | 1.10 |
| Erythromycin (≤0.25) | 2046 | − | − | 558 | 221 | 382 | 412 | 249 | 94 | 78 | 52 | − | − | 0.50 | 4.00 | 38.10 | 18.70 | 43.30 |
| Florfenicol (≤2) | 2046 | − | − | − | − | − | 1956 | 63 | 23 | 3 | 1 | − | − | 1.00 | 1.00 | 98.70 | 1.10 | 0.20 |
| Gentamicin (≤2) | 2046 | − | − | − | 66 | 28 | 79 | 1384 | 337 | 32 | 24 | 96 | − | 2.00 | 4.00 | 76.10 | 16.50 | 7.40 |
| Penicillin G 2 (≤0.25) | 2046 | − | 969 | 214 | 370 | 214 | 62 | 39 | 23 | 25 | 124 | 6 | − | 0.13 | 2.00 | 75.90 | 10.50 | 13.60 |
| Spectinomycin 3 (≤32) | 2046 | − | − | − | − | − | − | − | 277 | 1562 | 101 | 47 | 59 | 8.00 | 16.00 | 97.10 | 0.30 | 2.50 |
| Tiamulin (≤16) | 2046 | − | − | − | − | − | − | − | 1518 | 422 | 51 | 20 | 35 | 4.00 | 8.00 | 97.30 | − | 2.70 |
| Tilmicosin (≤16) | 2046 | − | − | − | − | − | 230 | 38 | 1557 | 73 | 65 | 30 | 53 | 4.00 | 8.00 | 95.94 | − | 4.10 |
| Tetracycline (≤0.5) | 2046 | − | − | 125 | 64 | 391 | 1121 | 100 | 66 | 48 | 65 | 65 | − | 1.00 | 4.00 | 28.40 | 54.80 | 16.80 |
| Tulathromycin 4 (≤16) | 325 | − | − | − | − | − | − | 272 | 25 | 10 | 11 | 5 | 2 | 2.00 | 4.00 | 97.80 | 1.50 | 0.60 |
Susceptibility and resistance of Gps isolates were assessed with respect to clinical breakpoints of the CLSI standards for Gps in swine. Bacterial isolates were categorized as “susceptible” (s), “intermediate” (i) or “resistant” (r). If no CLSI-approved clinical breakpoints for Gps were available, other published clinical breakpoints were used for assessment: 1 CLSI M100-S28 human, 2 CLSI VET08-A4 Pasteurella multocida swine, 3 CLSI VET08-A4 Pasteurella multocida cattle. 4 Tulathromycin was tested since 2017. The white area contains the dilution ranges tested. When isolates grew in the highest concentration of an antimicrobial agent, the corresponding MICs are considered to be equal to or higher than the next (not tested) concentration. − No isolates available.
Figure 1Frequencies of resistant isolates in the years 2006–2021 (n = 2046).
Univariable logistic regression model for comparison of resistant Gps isolates with respect to the sampling time period.
| Risk Categories | Resistant | Susceptible | Univariable Model | |||||
|---|---|---|---|---|---|---|---|---|
|
| % |
| % | OR | 95% CI |
| ||
| Lower | Upper | |||||||
| Ampicillin | ||||||||
| 2006–2013 (ref) | 180 | 14.48 | 1063 | 85.52 | 1 | x | x | x |
| 2014–2021 | 106 | 13.20 | 697 | 86.80 | 0.898 | 0.694 | 1.163 | 0.4148 |
| Ceftiofur | ||||||||
| 2006–2013 (ref) | 38 | 53.06 | 1250 | 96.94 | 1 | x | x | x |
| 2014–2021 | 4 | 0.50 | 799 | 99.50 | 0.159 | 0.056 | 0.447 | 0.0004 |
| Cephalothin * | ||||||||
| 2006–2013 (ref) | 1243 | 100.00 | 0 | 0.00 | 1 | x | x | x |
| 2014–2021 | 496 | 61.77 | 307 | 38.23 | n.d. | n.d. | n.d. | * |
| Colistin | ||||||||
| 2006–2013 (ref) | 105 | 8.45 | 1138 | 91.55 | 1 | x | x | x |
| 2014–2021 | 73 | 9.09 | 730 | 90.91 | 1.084 | 0.793 | 1.482 | 0.6141 |
| Enrofloxacin | ||||||||
| 2006–2013 (ref) | 64 | 5.15 | 1179 | 94.85 | 1 | x | x | x |
| 2014–2021 | 22 | 2.74 | 781 | 97.26 | 0.519 | 0.317 | 0.849 | 0.009 |
| Erythromycin | ||||||||
| 2006–2013 (ref) | 866 | 69.67 | 377 | 30.33 | 1 | x | x | x |
| 2014–2021 | 401 | 49.94 | 402 | 50.06 | 0.434 | 0.361 | 0.522 | <0.0001 |
| Florfenicol | ||||||||
| 2006–2013 (ref) | 21 | 1.69 | 1722 | 98.31 | 1 | x | x | x |
| 2014–2021 | 6 | 0.75 | 797 | 99.25 | 0.438 | 0.176 | 1.090 | 0.0760 |
| Gentamicin | ||||||||
| 2006–2013 (ref) | 305 | 24.54 | 938 | 75.46 | 1 | x | x | x |
| 2014–2021 | 184 | 22.91 | 619 | 77.09 | 0.914 | 0.742 | 1.127 | 0.4006 |
| Penicillin | ||||||||
| 2006–2013 (ref) | 304 | 24.46 | 939 | 75.54 | 1 | x | x | x |
| 2014–2021 | 189 | 23.54 | 614 | 76.46 | 0.951 | 0.772 | 1.171 | 0.6356 |
| Spectinomycin | ||||||||
| 2006–2013 (ref) | 49 | 3.94 | 1194 | 96.06 | 1 | x | x | x |
| 2014–2021 | 10 | 1.25 | 793 | 98.75 | 0.307 | 0.155 | 0.610 | 0.0007 |
| Tetracyclin * | ||||||||
| 2006–2013 (ref) | 1243 | 100.00 | 0 | 0.00 | 1 | x | x | x |
| 2014–2021 | 222 | 27.68 | 580 | 72.32 | n.d. | n.d. | n.d. | * |
| Tiamulin | ||||||||
| 2006–2013 (ref) | 48 | 3.86 | 1195 | 96.14 | 1 | x | x | x |
| 2014–2021 | 7 | 0.87 | 796 | 99.13 | 0.219 | 0.099 | 0.486 | 0.0002 |
| Tilmicosin | ||||||||
| 2006–2013 (ref) | 61 | 4.91 | 1182 | 95.09 | 1 | x | x | x |
| 2014–2021 | 22 | 2.74 | 781 | 97.26 | 0.546 | 0.332 | 0.896 | 0.0167 |
Univariable logistic regression analysis of proportion of resistant isolates to different antimicrobial substances with fixed effect time period (reference category is time period 2006–2013) as indicated by “ref.”. For tulathromycin, no data from the time period 2006–2013 existed. OR: point estimate/odds ratio, p: p-value of the Wald test, n: absolute number of isolates, %: percentage of isolates, n.d.: not determinable because model does not fit for this data set, * due to 100% resistant isolates in the time period 2006–2013 the statistical model cannot be applied to cephalothin and tetracyclin.
Multifactorial logistic regression analysis with fixed effect time period and factors “age group” and “sampling site” with respect to colistin, erythromycin, florfenicol and tetracyclin.
| Colistin |
|
|
|
| |||||
|
| % |
| % | OR |
| OR |
| ||
|
| 105 | 8.45 | 1138 | 91.55 | 1 | − | 1 | − | |
| 2014–2021 | 73 | 9.09 | 730 | 90.91 | 1.08 | 0.614 | 1.00 | 0.989 | |
| Age group |
| 124 | 8.29 | 1372 | 91.71 | 1 | − | 1 | − |
| Suckling piglet | 13 | 8.07 | 148 | 91.93 | 0.97 | 0.925 | 0.91 | 0.755 | |
| Fattening Pigs | 6 | 7.69 | 72 | 92.31 | 0.92 | 0.852 | 0.87 | 0.759 | |
| not specified | 35 | 11.44 | 271 | 88.56 | 1.43 | 0.078 | 1.46 | 0.072 | |
| Sampling site |
| 131 | 7.72 | 1566 | 92.28 | 1 | − | 1 | − |
| Pericardium | 22 | 15.83 | 117 | 84.17 | 2.25 | 0.001 | 2.38 | 0.001 | |
| Pleural cavity | 11 | 13.10 | 73 | 86.90 | 1.80 | 0.080 | 1.81 | 0.079 | |
| Brain | 9 | 12.86 | 61 | 87.14 | 1.76 | 0.124 | 1.77 | 0.124 | |
| Joints | 3 | 10.71 | 25 | 89.29 | 1.43 | 0.559 | 1.60 | 0.450 | |
| Abdominal cavity | 1 | 4.35 | 22 | 95.65 | 0.54 | 0.552 | 0.57 | 0.585 | |
| Erythromycin |
|
|
|
| |||||
|
| % |
| % | OR |
| OR |
| ||
| Time period |
| 866 | 69.67 | 377 | 30.33 | 1 | − | 1 | − |
| 2014–2021 | 401 | 49.94 | 402 | 50.06 | 0.43 | <0.001 | 0.45 | <0.001 | |
| Age group |
| 917 | 61.30 | 579 | 38.70 | 1 | − | 1 | − |
| Suckling piglet | 103 | 63.98 | 58 | 36.02 | 1.12 | 0.507 | 1.12 | 0.510 | |
| Fattening Pigs | 51 | 65.38 | 27 | 34.62 | 1.19 | 0.470 | 1.26 | 0.355 | |
| not specified | 193 | 63.07 | 113 | 36.93 | 1.08 | 0.561 | 0.946 | 0.682 | |
| Sampling site |
| 1073 | 63.23 | 624 | 36.77 | 1 | − | 1 | − |
| Pericardium | 75 | 53.96 | 64 | 46.04 | 0.68 | 0.031 | 0.79 | 0.201 | |
| Pleural cavity | 48 | 57.14 | 36 | 42.86 | 0.78 | 0.261 | 0.87 | 0.545 | |
| Brain | 39 | 55.71 | 31 | 44.29 | 0.73 | 0.204 | 0.80 | 0.385 | |
| Joints | 12 | 42.86 | 16 | 57.14 | 0.44 | 0.031 | 0.42 | 0.033 | |
| Abdominal cavity | 17 | 73.91 | 6 | 26.09 | 1.65 | 0.296 | 1.47 | 0.431 | |
| Florfenicol |
|
|
|
| |||||
|
| % |
| % | OR |
| OR |
| ||
| Time period |
| 21 | 1.69 | 1222 | 98.31 | 1 | − | 1 | − |
| 2014–2021 | 6 | 0.75 | 797 | 99.25 | 0.44 | 0.076 | 0.42 | 0.062 | |
| Age group | Nursery pigs (Ref.) | 19 | 1.27 | 1477 | 98.73 | 1 | − | 1 | − |
| Suckling piglet | 1 | 0.62 | 160 | 99.38 | 0.49 | 0.483 | 0.48 | 0.471 | |
| Fattening Pigs | 4 | 5.13 | 74 | 94.87 | 4.20 | 0.011 | 4.29 | 0.009 | |
| Not specified | 3 | 0.98 | 303 | 99.02 | 0.77 | 0.675 | 0.696 | 0.564 | |
| Sampling site | Respiratory tract (Ref.) | 25 | 1.47 | 1672 | 98.53 | 1 | − | 1 | − |
| Pericardium | − | − | 139 | 100.00 | − | − | −- | − | |
| Pleural cavity | 2 | 2.38 | 82 | 97.62 | 1.63 | 0.510 | − | − | |
| Brain | − | − | 70 | 100.00 | − | − | − | − | |
| Joints | − | − | 28 | 100.00 | − | − | − | − | |
| Abdominal cavity | − | − | 23 | 100.00 | − | − | − | − | |
| Tetracyclin |
|
|
|
| |||||
|
| % |
| % | OR |
| OR |
| ||
| Time period | 2006–2013 (Ref.) | 1243 | 100.00 | − | − | − | − | − | − |
| 2014–2021 | 222 | 27.68 | 580 | 72.32 | 1 | − | 1 | − | |
| Age group | Nursery pigs (Ref.) | 1044 | 69.83 | 451 | 30.17 | 1 | − | 1 | − |
| Suckling piglet | 120 | 74.53 | 41 | 25.47 | 1.26 | 0.216 | 1.32 | 0.146 | |
| Fattening Pigs | 56 | 71.79 | 22 | 28.21 | 1.10 | 0.713 | 1.16 | 0.560 | |
| Not specified | 240 | 78.43 | 66 | 21.57 | 1.57 | 0.003 | 1.66 | 0.001 | |
| Sampling site | Respiratory tract (Ref.) | 1248 | 73.58 | 448 | 26.42 | 1 | − | 1 | − |
| Pericardium | 81 | 58.27 | 58 | 41.73 | 0.50 | <0.001 | 0.50 | 0.0001 | |
| Pleural cavity | 55 | 65.48 | 29 | 34.52 | 0.68 | 0.103 | 0.68 | 0.097 | |
| Brain | 41 | 58.57 | 29 | 41.43 | 0.51 | 0.006 | 0.49 | 0.005 | |
| Joints | 20 | 71.43 | 8 | 28.57 | 0.90 | 0.798 | 0.86 | 0.725 | |
| Abdominal cavity | 19 | 82.61 | 4 | 17.39 | 1.71 | 0.334 | 1.78 | 0.297 | |
Reference categories for the logistic regression method (time period 2006–2013, nursery pigs, respiratory tract) are highlighted in bold and indicated by “Ref.”. Univariable log. reg.: One-factorial logistic regression model, multivariable log.reg.: Multi-factorial logistic regression model, OR: point estimate/odds ratio, p: p-value of the Wald test, n: absolute number of isolates, %: proportion of isolates. −No isolates available.
Proportion of resistant Gps isolates from the respiratory tract of nursery pigs in the time periods 2006–2013 and 2014–2021.
| Antimicrobial Substance | 2006–2013 | 2014–2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Resistant Isolates | Sensitive Isolates | Resistant Isolates | Sensitive Isolates | ||||||
| Number | (%) | Number | (%) | Number | (%) | Number | (%) | ||
| Ampicillin | 105 | 13.74 | 659 | 86.26 | 64 | 13.11 | 424 | 86.89 | 0.751 |
| Ceftiofur | 24 | 3.14 | 740 | 96–86 | 4 | 0.82 | 484 | 99.18 | 0.012 |
| Cephalothin | 764 | 100.00 | − | − | 288 | 59.02 | 200 | 40.98 | n.d. |
| Colistin | 50 | 6.54 | 714 | 93.46 | 40 | 8.20 | 448 | 91.80 | 0.271 |
| Enrofloxacin | 33 | 4.32 | 731 | 95.68 | 15 | 3.07 | 473 | 69.93 | 0.265 |
| Erythromycin | 540 | 70.68 | 224 | 29.32 | 244 | 50.00 | 244 | 50.00 | <0.0001 |
| Florfenicol | 13 | 1.70 | 751 | 98.30 | 5 | 1.02 | 483 | 98.98 | 0.331 |
| Gentamicin | 186 | 24.35 | 578 | 75.65 | 119 | 24.39 | 369 | 75.61 | 0.987 |
| Penicillin | 173 | 22.64 | 591 | 77.36 | 112 | 22.95 | 376 | 77.05 | 0.899 |
| Spectinomycin | 28 | 3.66 | 736 | 96.34 | 6 | 1.23 | 482 | 98.77 | 0.014 |
| Tetracyclin | 764 | 100.00 | − | − | 133 | 27.31 | 354 | 72.69 | n.d. |
| Tiamulin | 33 | 4.32 | 731 | 95.68 | 4 | 0,82 | 484 | 99.18 | 0.001 |
| Tilmicosin | 38 | 4.97 | 726 | 95.03 | 15 | 3.07 | 473 | 96.93 | 0.107 |
* Significant differences according to linear logistic regression models. − No isolates available.
Microorganisms in samples positive for Gps.
| Additional Microorganisms in Samples Positive for Gps | Combinations with Gps | Number of Samples Tested | ||||
|---|---|---|---|---|---|---|
| Negative | Positive | |||||
|
| % |
| % |
| ||
| Type | Pathogen | |||||
| Virus a | Influenza | 730 | 77.00 | 218 | 23.00 | 948 |
| PCV2 | 633 | 82.00 | 139 | 18.00 | 772 | |
| PRRSV-EU | 818 | 74.9 | 274 | 25.10 | 1092 | |
| PRSV-US | 977 | 90.70 | 100 | 9.30 | 1077 | |
| Bacteria |
| 2000 | 97.80 | 46 | 2.20 | 2046 |
|
| 2045 | 100.00 | 1 | 0.00 | 2046 | |
|
| 1992 | 97.40 | 54 | 2.60 | 2046 | |
|
| 1824 | 89.10 | 222 | 10.90 | 2046 | |
|
| 739 | 86.80 | 112 | 13.20 | 851 | |
|
| 308 | 54.90 | 253 | 45.10 | 561 | |
|
| 2016 | 98.50 | 30 | 1.50 | 2046 | |
|
| 1526 | 74.60 | 520 | 25.40 | 2046 | |
|
| 1873 | 91.20 | 173 | 8.50 | 2046 | |
a detection by PCR, * detection by cultural microbiological methods.
The used clinical cut-offs for Glaesserella parasuis.
| Antimicrobial Substance | Sensitive | Intermediate | Resistant |
|---|---|---|---|
| Ampicillin | ≤0.5 | 1 | ≥ 2 |
| Ceftiofur | ≤2 | 4 | ≥8 |
| Cephalotin | ≤2 | 4 | ≥8 |
| Colistin | ≤0.5 | 1–2 | ≥4 |
| Enrofloxacin | ≤0.25 | 0.5 | ≥1 |
| Erythromycin | ≤0.25 | 0.5 | ≥1 |
| Florfenicol | ≤2 | 4 | ≥8 |
| Gentamicin | ≤2 | 4 | ≥8 |
| Penicillin | ≤0.25 | 0.5 | ≥1 |
| Spectinomycin | ≤32 | 64 | >64 |
| Tetracyclin | ≤0.5 | 1 | ≥2 |
| Tiamulin | ≤16 | − | ≥32 |
| Tilmicosin | ≤16 | − | ≥32 |
| Tulathromycin | ≤16 | 32 | ≥64 |
− not specified.